Fathom Therapeutics logo — The molecular frontier

Fathom Therapeutics

The molecular frontier

Founded 2023 United States New York, United States 22 employees Seed Total: $7.08M Biopharma, Biotechnology

General Information

Company Name Fathom Therapeutics
Founded Year 2023
Location United States New York, United States +1
Employees 22
Industries Biopharma, Biotechnology
Funding Stage Seed
Social

Get notified when Fathom Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Fathom Therapeutics

Atommap, founded in 2023, is at the forefront of innovation in the Biopharma and Biotechnology sectors. With its slogan, "We invent molecules to better health and life," the company emphasizes its dedication to advancing health through cutting-edge science and technology.

The company specializes in the invention of therapeutic molecules, leveraging a combination of quantum physics, artificial intelligence, and computation-driven design to achieve atomic precision. This innovative approach places Atommap as a unique player poised to deliver significant advancements in medical treatments.

Headquartered in the United States, Atommap recently secured a $7.08M Seed Round investment on November 13, 2023, demonstrating strong investor confidence in its potential. While investor names weren't disclosed, this seed funding is critical in propelling the company's early-stage development.

Taxonomy: therapeutic molecules, quantum physics, AI in pharmaceuticals, computation-driven design, atomic precision, molecule design, healthtech innovation, drug discovery, advanced therapeutics, quantum computing in healthcare, AI-driven drug design

Services & Products

Computational modeling and simulation
Generative design of therapeutics
High-throughput therapeutic potency evaluation
Drug candidate delivery and optimization

Target Customers

Pharmaceutical companies Biotechnology firms Research and development institutions

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• - 13 Nov 2023
Pre Seed Round •••••• 1 •••• •••• 28 Feb 2023

Fathom Therapeutics Alternatives & Competitors

View All Alternatives
Fathom Therapeutics vs
Creyon Bio
Creyon Bio United States

Delivering RNA breakthroughs. Redefining hope.

Series A
31 employees
Biotechnology, Life Sciences
Fathom Therapeutics vs

We build generative AI for protein therapeutics.

Unknown
11 employees
Biotechnology, Pharmaceutical
Fathom Therapeutics vs

Ikena merged with ImageneBio on in July 2025. Please visit https://inmagenebio.com/ for more informa...

Post Ipo Equity
14 employees
Biotechnology, Health Care

FAQ About Fathom Therapeutics

The molecular frontier
Fathom Therapeutics was founded in 2023.
Fathom Therapeutics is headquartered in New York, United States.
Fathom Therapeutics operates in the following industries: Biopharma, Biotechnology.
Fathom Therapeutics has approximately 22 employees.
Fathom Therapeutics has completed 2 funding rounds, raising a total of $7.08M. The latest funding stage is Seed.
Fathom Therapeutics offers: Computational modeling and simulation, Generative design of therapeutics, High-throughput therapeutic potency evaluation, Drug candidate delivery and optimization.
Top alternatives and competitors to Fathom Therapeutics include Creyon Bio, Diffuse Bio, Ikena Oncology (Merged with ImageneBio), METiS Pharmaceuticals, Synamics Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Fathom Therapeutics and Creyon Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Fathom Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy